Randomized Study Comparing Conventional Dose Treatment Using a Combination of Lenalidomide, Bortezomib and Dexamethasone to High-Dose Treatment With ASCT in the Initial Management of Myeloma in Patients up to 65 Years of Age

Trial Profile

Randomized Study Comparing Conventional Dose Treatment Using a Combination of Lenalidomide, Bortezomib and Dexamethasone to High-Dose Treatment With ASCT in the Initial Management of Myeloma in Patients up to 65 Years of Age

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 30 May 2018

At a glance

  • Drugs Bortezomib (Primary) ; Dexamethasone (Primary) ; Lenalidomide (Primary) ; Melphalan
  • Indications Multiple myeloma
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 27 May 2018 This trial has been completed in France (end date: 2016-11-30)
    • 10 Jun 2017 Biomarkers information updated
    • 06 Apr 2017 Primary endpoint of progression free survival has been met, according to results published in the New England Journal of Medicine.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top